Gencor Industries Company Profile (NASDAQ:GENC)

About Gencor Industries

Gencor Industries logo

Gencor Industries, Inc. is a manufacturer of heavy machinery used in the production of highway construction materials, synthetic fuels, and environmental control equipment. The Company designs, manufactures, and sells machinery and related equipment used for the production of asphalt and highway construction materials. The Company's products include asphalt plants, combustion systems and fluid heat transfer systems. The Company's products are manufactured in approximately two facilities in the United States. The Company manufactures and produces hot-mix asphalt plants used in the production of asphalt paving materials. The Company manufactures related asphalt plant equipment, including hot mix storage silos, fabric filtration systems, cold feed bins and other plant components. The Company also manufactures Combustion Systems and Industrial Incinerators, and Fluid Heat Transfer Systems.

Industry, Sector and Symbol:

Sector: Industrial Products
Industry: Farm & Construction Machinery
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: GENC
CUSIP:

Key Metrics:

Previous Close: $11.66
50 Day Moving Average: $11.58
200 Day Moving Average: $10.40
52-Week Range: $14,336,000.00 - $5.95
Trailing P/E Ratio: 53.73
Foreward P/E Ratio: 29.15
P/E Growth: 0.00
Market Cap: $167.16M
Outstanding Shares: 14,336,000
Beta: 0.41

Profitability:

Net Margins: 4.86%
Return on Equity: 2.68%
Return on Assets: 2.49%

Debt:

Current Ratio: 15.68%
Quick Ratio: 14.17%

Additional Links:

Companies Related to Gencor Industries:

Consensus Ratings for Gencor Industries (NASDAQ:GENC) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Gencor Industries (NASDAQ:GENC)

Show:

No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Gencor Industries (NASDAQ:GENC)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
12/6/2016
12/9/2014		$0.06	($0.06)			View	N/A
8/5/2014		$0.14	$0.17			View	N/A
2/7/2014	Q1 14		$0.05			View	N/A
12/13/2013	Q4		$0.24			View	N/A
2/11/2013	Q1 2013		($0.10)	$6.90 million	$4.90 million	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Gencor Industries (NASDAQ:GENC)

Current Year EPS Consensus Estimate: $0.34 EPS
Next Year EPS Consensus Estimate: $0.40 EPS

Dividend History for Gencor Industries (NASDAQ:GENC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Gencor Industries (NASDAQ:GENC)

Insider Ownership Percentage: 31.87%
Institutional Ownership Percentage: 15.71%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/29/2016	Lawrence Maingot	VP	Sell	1,500	$12.00	$18,000.00
8/17/2016	Eric E Mellen	CFO	Buy	10,000	$10.75	$107,500.00
7/27/2016	Sherry Houtkin	Major Shareholder	Sell	4,718	$17.91	$84,499.38
7/26/2016	Sherry Houtkin	Major Shareholder	Sell	7,000	$17.31	$121,170.00
7/22/2016	Sherry Houtkin	Major Shareholder	Sell	2,000	$16.88	$33,760.00
7/21/2016	Sherry Houtkin	Major Shareholder	Sell	10,000	$16.85	$168,500.00
7/19/2016	Sherry Houtkin	Major Shareholder	Sell	6,000	$16.87	$101,220.00
7/15/2016	Sherry Houtkin	Major Shareholder	Sell	13,541	$16.74	$226,676.34
7/13/2016	Sherry Houtkin	Major Shareholder	Sell	15,000	$16.00	$240,000.00
7/12/2016	Sherry Houtkin	Major Shareholder	Sell	5,000	$15.51	$77,550.00
7/11/2016	Sherry Houtkin	Major Shareholder	Sell	10,251	$15.26	$156,430.26
7/7/2016	Sherry Houtkin	Major Shareholder	Sell	11,890	$15.07	$179,182.30
6/7/2016	Marc G Elliott	President	Sell	15,000	$14.91	$223,650.00
6/3/2016	Marc G Elliott	President	Sell	2,000	$14.74	$29,480.00
5/16/2016	Marc G Elliott	President	Sell	24,000	$14.86	$356,640.00
3/3/2016	David Air	Director	Sell	5,000	$13.40	$67,000.00
3/2/2016	Sherry Houtkin	Major Shareholder	Sell	10,000	$13.38	$133,800.00
3/1/2016	Sherry Houtkin	Major Shareholder	Sell	20,000	$13.54	$270,800.00
2/26/2016	Sherry Houtkin	Major Shareholder	Sell	50,000	$13.11	$655,500.00
2/17/2016	Marc G. Elliott	President	Sell	9,140	$12.68	$115,895.20
12/15/2015	Marc G. Elliott	President	Sell	19,044	$12.74	$242,620.56
10/6/2015	Sherry Houtkin	Major Shareholder	Sell	80,000	$9.26	$740,800.00
5/6/2015	Sherry Houtkin	Major Shareholder	Sell	70,000	$9.20	$644,000.00
12/8/2014	Sherry Houtkin	Major Shareholder	Sell	2,948	$9.72	$28,654.56
12/2/2014	Sherry Houtkin	Major Shareholder	Sell	5,000	$9.93	$49,650.00
11/25/2014	Sherry Houtkin	Major Shareholder	Sell	200,000	$9.25	$1,850,000.00
9/2/2014	Sherry Houtkin	Major Shareholder	Sell	5,000	$10.18	$50,900.00
8/26/2014	Sherry Houtkin	Major Shareholder	Sell	5,346	$10.23	$54,689.58
8/25/2014	Sherry Houtkin	Major Shareholder	Sell	344	$10.20	$3,508.80
8/21/2014	Sherry Houtkin	Major Shareholder	Sell	4,984	$10.18	$50,737.12
8/20/2014	Sherry Houtkin	Major Shareholder	Sell	2,200	$10.16	$22,352.00
8/19/2014	Sherry Houtkin	Major Shareholder	Sell	1,208	$10.20	$12,321.60
3/11/2014	Jeanne M Lyons	Insider	Sell	1,500	$10.93	$16,395.00
2/20/2014	Jeanne M Lyons	Insider	Sell	2,000	$10.97	$21,940.00
2/19/2014	Eric E Mellen	CFO	Sell	11,051	$11.07	$122,334.57
10/14/2013	Sherry Houtkin	Major Shareholder	Sell	80,086	$8.80	$704,756.80

(Data available from 1/1/2013 forward)

Latest Headlines for Gencor Industries (NASDAQ:GENC)

Date	Headline
	Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL (NASDAQ:GENC) www.publicnow.com - August 31 at 9:54 AM
	Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine (NASDAQ:GENC) www.publicnow.com - August 25 at 10:12 AM
	Genmab Announces European Regulatory Submission for Daratumumab in Relapsed Multiple Myeloma (NASDAQ:GENC) www.publicnow.com - August 23 at 9:32 AM
	Articles of Association for Genmab A/S (NASDAQ:GENC) www.publicnow.com - August 18 at 5:13 PM
	Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (NASDAQ:GENC) www.publicnow.com - August 17 at 5:26 PM
	GENCOR INDUSTRIES INC Financials (NASDAQ:GENC) finance.yahoo.com - August 17 at 5:26 PM
	Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Relapsed Multiple Myeloma (NASDAQ:GENC) www.publicnow.com - August 17 at 5:26 PM
	ETF’s with exposure to Gencor Industries, Inc. : August 16, 2016 (NASDAQ:GENC) www.capitalcube.com - August 16 at 5:21 PM
	Gencor Industries, Inc. :GENC-US: Earnings Analysis: Q3, 2016 By the Numbers : August 12, 2016 (NASDAQ:GENC) www.capitalcube.com - August 12 at 5:15 PM
	Genmab Enters Commercial License Agreement with Gilead for DuoBody® Technology (NASDAQ:GENC) www.publicnow.com - August 10 at 5:26 PM
	Gencor Sales Up 82.6% in 3Q (NASDAQ:GENC) www.mdm.com - August 9 at 9:32 PM
	Gencor Releases Third Quarter Fiscal 2016 Results (NASDAQ:GENC) www.nasdaq.com - August 9 at 9:32 PM
	Gencor posts 3Q profit (NASDAQ:GENC) sg.finance.yahoo.com - August 9 at 3:56 PM
	Genmab Announces Financial Results for the First Half of 2016 and Improves 2016 Financial Guidance (NASDAQ:GENC) www.publicnow.com - August 9 at 3:56 PM
	Genmab Appoints Board Observer (NASDAQ:GENC) www.publicnow.com - August 3 at 8:07 AM
	Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in Combination with Standard of Care Regimens for Previously Treated Multiple Myeloma (NASDAQ:GENC) www.publicnow.com - July 25 at 8:18 PM
	Splits Calendar: Gencor Industries splits before market open today (3:2 ratio) (NASDAQ:GENC) biz.yahoo.com - July 22 at 7:03 AM
	ETF’s with exposure to Gencor Industries, Inc. : July 18, 2016 (NASDAQ:GENC) www.capitalcube.com - July 18 at 1:49 PM
	CSE: 2016-0704 - Delist - GoviEx Uranium Inc. (GXU) (NASDAQ:GENC) www.4-traders.com - July 12 at 9:36 AM
	GENCOR INDUSTRIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:GENC) biz.yahoo.com - July 11 at 3:20 PM
	10:17 am Gencor Industries announces a 3:2 stock split on class B shares in the form of a 50% dividend, ex split date is Aug 1 (NASDAQ:GENC) finance.yahoo.com - July 11 at 10:17 AM
	Gencor Announces 50% Stock Dividend (NASDAQ:GENC) finance.yahoo.com - July 11 at 10:14 AM
	ETF’s with exposure to Gencor Industries, Inc. : July 7, 2016 (NASDAQ:GENC) www.capitalcube.com - July 7 at 2:56 PM
	Genmab Provides Update on Marketing Authorization Application for Arzerra® (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL (NASDAQ:GENC) www.publicnow.com - June 23 at 10:29 AM
	Grant of Warrants to Genmab Employees (NASDAQ:GENC) www.publicnow.com - June 9 at 12:59 PM
	Gencor Industries, Inc. :GENC-US: Earnings Analysis: Q2, 2016 By the Numbers : June 8, 2016 (NASDAQ:GENC) www.capitalcube.com - June 8 at 9:45 AM
	Genmab's Total Number of Voting Rights and Total Share Capital (NASDAQ:GENC) www.publicnow.com - May 31 at 11:12 AM
	Genmab to Present at the Goldman Sachs 37th Annual Global Healthcare Conference (NASDAQ:GENC) www.publicnow.com - May 31 at 3:22 AM
	Genmab Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collaboration with Janssen (NASDAQ:GENC) www.publicnow.com - May 30 at 11:10 AM
	Genmab Achieves USD 30 Million Milestone in DARZALEX® (daratumumab) Collaboration with Janssen (NASDAQ:GENC) www.publicnow.com - May 30 at 11:10 AM
	Genmab Announces European Conditional Marketing Authorization for DARZALEX® (daratumumab) for Multiple Myeloma (NASDAQ:GENC) www.publicnow.com - May 23 at 6:56 AM
	First Participants Dosed in Clinical Study with DuoBody® Product (NASDAQ:GENC) www.publicnow.com - May 20 at 3:33 AM
	Daratumumab and Ofatumumab Data to Be Presented at 21st Congress of EHA (NASDAQ:GENC) www.publicnow.com - May 19 at 7:22 AM
	Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma (NASDAQ:GENC) www.publicnow.com - May 18 at 2:32 PM
	Capital Increase in Genmab as a Result of Employee Warrant Exercise (NASDAQ:GENC) www.publicnow.com - May 18 at 12:02 PM
	Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA (NASDAQ:GENC) www.publicnow.com - May 17 at 4:12 PM
	Genmab Announces Financial Results for the First Quarter of 2016 (NASDAQ:GENC) www.publicnow.com - May 10 at 11:18 AM
	Gencor posts 2Q profit (NASDAQ:GENC) sg.finance.yahoo.com - May 9 at 7:36 PM
	Gencor Releases Second Quarter Fiscal 2016 Results (NASDAQ:GENC) finance.yahoo.com - May 9 at 4:30 PM
	Gencor Industries Incorporated (NASDAQ:GENC) Sellers Covered 29.52% of Their Shorts (NASDAQ:GENC) www.bibeypost.com - April 22 at 10:59 AM
	Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting (NASDAQ:GENC) www.publicnow.com - April 20 at 10:51 AM
	Genmab Updates Financial Guidance for 2016 (NASDAQ:GENC) www.publicnow.com - April 20 at 1:12 AM
	Gencor Industries Inc. (GENC) (NASDAQ:GENC) finance.yahoo.com - April 15 at 2:06 PM
	ETF’s with exposure to Gencor Industries, Inc. : April 8, 2016 (NASDAQ:GENC) www.capitalcube.com - April 8 at 5:35 PM
	Gencor Industries, Inc. :GENC-US: Earnings Analysis: Q1, 2016 By the Numbers (NASDAQ:GENC) www.capitalcube.com - April 7 at 10:13 AM
	Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX® (NASDAQ:GENC) www.publicnow.com - April 4 at 2:05 PM
	CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed and Refractory Multiple Myeloma (NASDAQ:GENC) www.publicnow.com - April 1 at 11:41 AM
	Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma (NASDAQ:GENC) www.publicnow.com - March 30 at 12:21 PM
	GENCOR INDUSTRIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:GENC) biz.yahoo.com - March 10 at 5:01 PM
	Insider Trading Alert - GENC, LPLA And RMD Traded By Insiders (NASDAQ:GENC) www.thestreet.com - March 5 at 2:39 PM